ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 690,67
1,27%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Spero Therapeutics Inc (SPRO)

  7. Spero Therapeutics Inc (SPRO) Actualités

SPRO Spero Therapeutics Inc

1,65
0,04 (2,48%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Spero Therapeutics Inc SPRO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,04 2,48% 1,65 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,63 1,62 1,6494 1,63 1,61
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/3/202414:05GLOBESpero Therapeutics to Provide Business Update and Report..
28/2/202414:05GLOBESpero Therapeutics Announces Clearance of IND for SPR206 to..
26/2/202414:05GLOBESpero Therapeutics to Present at Cowen’s 44th Annual..
09/2/202422:05EDGAR2Form 8-K - Current report
06/2/202402:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202402:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202402:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:50EDGAR2Form 144 - Report of proposed sale of securities
31/1/202422:05GLOBESpero Therapeutics Announces Inducement Grants Under Nasdaq..
08/1/202412:07EDGAR2Form 8-K - Current report
05/1/202414:11EDGAR2Form 8-K - Current report
05/1/202414:05GLOBESpero Therapeutics Provides Corporate Update and 2024..
04/1/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202414:13EDGAR2Form 8-K - Current report
02/1/202414:05GLOBESpero Therapeutics Announces First Patient, First Visit for..
15/11/202322:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202322:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/11/202322:50EDGAR2Form S-8 - Securities to be offered to employees in employee..
13/11/202322:45EDGAR2Form S-8 - Securities to be offered to employees in employee..
13/11/202322:13EDGAR2Form 8-K - Current report
13/11/202322:05GLOBESpero Therapeutics Announces Third Quarter 2023 Operating..
13/11/202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202312:45IHMARKETNEWSMonday’s Wall Street Highlights: Boeing, Novo Nordisk,..
06/11/202314:05GLOBESpero Therapeutics to Provide Business Update and Report..
01/11/202321:05GLOBESpero Therapeutics to Present at Upcoming November Investor..
01/11/202313:10EDGAR2Form 8-K - Current report
01/11/202313:05GLOBESpero Therapeutics Appoints Esther Rajavelu as Chief..
31/10/202321:05GLOBESpero Therapeutics Announces Inducement Grants Under Nasdaq..
16/10/202322:01EDGAR2Form 8-K/A - Current report: [Amend]
10/10/202323:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202314:28EDGAR2Form 8-K - Current report
29/9/202322:05GLOBESpero Therapeutics Announces Inducement Grants Under Nasdaq..
20/9/202322:05GLOBESpero Therapeutics to Present at Cantor’s Global Healthcare..
15/9/202323:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202314:05GLOBESpero Therapeutics to Present at H.C. Wainwright 25th Annual..
01/9/202322:11EDGAR2Form ARS - Annual Report to Security Holders
01/9/202322:08EDGAR2Form DEF 14A - Other definitive proxy statements
31/8/202322:05GLOBESpero Therapeutics Announces Inducement Grants Under Nasdaq..
30/8/202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202322:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:16EDGAR2Form 144 - Report of proposed sale of securities
22/8/202323:27EDGAR2Form PRE 14A - Other preliminary proxy statements
10/8/202322:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/8/202322:17EDGAR2Form 8-K - Current report
10/8/202322:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:05GLOBESpero Therapeutics Announces Second Quarter 2023 Operating..

Dernières Valeurs Consultées

NASDAQ
SPRO
Spero Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés